Zhikun Yin1, Ji Li2, Weifeng Huang2, Xiaoyi Lei1, Dong Xu2, Guihua Xu2, Hua Li2, Jinyan Zhang1. 1. Fujian Medical University The Third Clinical Medical College, Fuzhou, Fujian, China; Department of Gastroenterology, The First Affiliated Hospital of Xiamen University Faculty of Medicine, Xiamen, China. 2. Department of Gastroenterology, The First Affiliated Hospital of Xiamen University Faculty of Medicine, Xiamen, China.
Abstract
BACKGROUND: This study aimed to evaluate the efficacy and safety of high-dose dual therapy for Helicobacter pylori (H. pylori) eradication compared to bismuth-containing quadruple therapy. METHODS: The electronic database of PubMed, Embase, and Cochrane Library were searched from inception to March 18, 2021. Randomized, controlled trials that evaluated high-dose dual therapy versus bismuth-containing quadruple therapy for H. pylori infection were included. RESULTS: We included 6 studies containing 1677 patients with H. pylori infection. This meta-analysis demonstrated that high-dose dual therapy achieved similar eradication rate compared with bismuth-containing quadruple therapy (intention-to-treat: 84.6% vs 83.7%, relative risk (RR) = 1.01, 95% CI: 0.97-1.06, P = .49; per-protocol = 88.4% vs 89.0%, RR = 1.00, 95% CI: 0.97-1.04, P = .99). However, highdose dual therapy showed fewer side effects (13.1% vs 32.0%, RR = 0.51, 95% CI: 0.34-0.78, P = .002) and better compliance (96.1% vs 93.3%, RR = 1.03, 95% CI: 1.00-1.05, P = .03) compared to bismuth-containing quadruple therapy. CONCLUSION: This meta-analysis demonstrated that high-dose dual therapy is equally effective with bismuth-containing quadruple therapy in eradicating H. pylori, with fewer side effects and better compliance.
BACKGROUND: This study aimed to evaluate the efficacy and safety of high-dose dual therapy for Helicobacter pylori (H. pylori) eradication compared to bismuth-containing quadruple therapy. METHODS: The electronic database of PubMed, Embase, and Cochrane Library were searched from inception to March 18, 2021. Randomized, controlled trials that evaluated high-dose dual therapy versus bismuth-containing quadruple therapy for H. pylori infection were included. RESULTS: We included 6 studies containing 1677 patients with H. pylori infection. This meta-analysis demonstrated that high-dose dual therapy achieved similar eradication rate compared with bismuth-containing quadruple therapy (intention-to-treat: 84.6% vs 83.7%, relative risk (RR) = 1.01, 95% CI: 0.97-1.06, P = .49; per-protocol = 88.4% vs 89.0%, RR = 1.00, 95% CI: 0.97-1.04, P = .99). However, highdose dual therapy showed fewer side effects (13.1% vs 32.0%, RR = 0.51, 95% CI: 0.34-0.78, P = .002) and better compliance (96.1% vs 93.3%, RR = 1.03, 95% CI: 1.00-1.05, P = .03) compared to bismuth-containing quadruple therapy. CONCLUSION: This meta-analysis demonstrated that high-dose dual therapy is equally effective with bismuth-containing quadruple therapy in eradicating H. pylori, with fewer side effects and better compliance.
Authors: Carlo A Fallone; Naoki Chiba; Sander Veldhuyzen van Zanten; Lori Fischbach; Javier P Gisbert; Richard H Hunt; Nicola L Jones; Craig Render; Grigorios I Leontiadis; Paul Moayyedi; John K Marshall Journal: Gastroenterology Date: 2016-04-19 Impact factor: 22.682
Authors: T Kagami; S Sahara; H Ichikawa; T Uotani; M Yamade; M Sugimoto; Y Hamaya; M Iwaizumi; S Osawa; K Sugimoto; H Miyajima; T Furuta Journal: Aliment Pharmacol Ther Date: 2016-03-18 Impact factor: 8.171